Back to search results

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Abroad (travel likely)RecruitingPHASE1

Conditions

Mantle Cell Lymphoma · Follicular Lymphoma · Splenic Marginal Zone Lymphoma · Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma · Indolent Non-hodgkin Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States

    Contact: Study coordinator (Catherine Cheng) · UNCImmunotherapy@med.unc.edu · 919-445-4208
    Contact: Study coordinator (Kelly Hoye) · UNCImmunotherapy@med.unc.edu · 919-445-9676
    Contact: Principal Investigator (Natalie Grover, MD)
    Paul Armistead (Sub-investigator)
    Anne Beaven, MD (Sub-investigator)
    James Coghill (Sub-investigator)
    Christopher Dittus, MD (Sub-investigator)
    Gianpietro Dotti (Sub-investigator)
    Paul Eldridge (Sub-investigator)
    Katarzyna Jamieson (Sub-investigator)
    Emily Kassam (Sub-investigator)
    Grace Park (Sub-investigator)
    Alicia Pinto (Sub-investigator)
    Marcie Riches (Sub-investigator)
    Barbara Savoldo (Sub-investigator)
    Jonathan Serody, MD (Sub-investigator)
    Thomas Shea, MD (Sub-investigator)
    Benjamin Vincent (Sub-investigator)
    Kimberly Wehner (Sub-investigator)
    William Wood (Sub-investigator)
    Ashley Zanter (Sub-investigator)
Study leads

  • Natalie Grover, MD

    Principal Investigator

    UNC Lineberger Comprehensive Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)